ID: ALA2431665

Max Phase: Preclinical

Molecular Formula: C20H17Cl2O5P

Molecular Weight: 439.23

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=P(O)(O)[C@H](O)c1ccc(-c2cccc([C@H](O)c3ccc(Cl)c(Cl)c3)c2)cc1

Standard InChI:  InChI=1S/C20H17Cl2O5P/c21-17-9-8-16(11-18(17)22)19(23)15-3-1-2-14(10-15)12-4-6-13(7-5-12)20(24)28(25,26)27/h1-11,19-20,23-24H,(H2,25,26,27)/t19-,20-/m0/s1

Standard InChI Key:  KYNFSOSPDJUFDE-PMACEKPBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 439.23

Molecular Weight (Monoisotopic): 438.0191

AlogP: 4.91

#Rotatable Bonds: 5

Polar Surface Area: 97.99

Molecular Species: ACID

HBA: 3

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.22

CX Basic pKa:

CX LogP: 3.99

CX LogD: 1.54

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.42

Np Likeness Score: -0.23

References

1. Baguley TD, Xu HC, Chatterjee M, Nairn AC, Lombroso PJ, Ellman JA..  (2013)  Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase.,  56  (19): [PMID:24083656] [10.1021/jm401037h]

2. Witten MR, Wissler L, Snow M, Geschwindner S, Read JA, Brandon NJ, Nairn AC, Lombroso PJ, Käck H, Ellman JA..  (2017)  X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.,  60  (22): [PMID:29116812] [10.1021/acs.jmedchem.7b01292]

3. Hou X,Sun JP,Ge L,Liang X,Li K,Zhang Y,Fang H.  (2020)  Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets.,  190  [PMID:32078861] [10.1016/j.ejmech.2020.112131]

Source

Source(1):

• Scientific Literature